Novartis Partial Clinical Trial Hold for OAV-101 IT for SMA Lifted
Novartis (NVS) announced that the U.S. FDA has determined that OAV-101 intrathecal (IT) clinical trials for spinal muscular atrophy (SMA) patients may proceed, thereby lifting the partial clinical trial hold initiated in October 2019.

The decision to lift the hold was based on data from . . .